A number of stock research firms have changed their ratings and price targets for Watson Pharmaceuticals Incorporated (NYSE: WPI) during the last seven days:Watson Pharmaceuticals Incorporated had its “overweight” rating re-affirmed by analysts at Piper Jaffray. They now have a $78.00 price target on the stock.Watson Pharmaceuticals Incorporated had its “buy” rating re-affirmed by analysts at Canaccord Genuity.Watson Pharmaceuticals Incorporated had its price target lowered by analysts at Piper Jaffray from $78.00 to $73.00.Watson Pharmaceuticals Incorporated had its “buy” rating re-affirmed by analysts at UBS AG.Watson Pharmaceuticals Incorporated had its “hold” rating re-affirmed by analysts at Needham & Company.Watson Pharmaceuticals Incorporated ‘s EPS estimates were cut by analysts at Credit Suisse. They now have an “outperform” rating and a $77.00 price target on the stock.Watson Pharmaceuticals Incorporated had its “conviction buy” rating re-affirmed by analysts at Goldman Sachs.Watson Pharmaceuticals Incorporated was downgraded by analysts at Citigroup from a “buy” rating to a “neutral” rating.Watson Pharmaceuticals Incorporated was downgraded by analysts at Cowen from an “outperform” rating to a “neutral” rating.Watson Pharmaceuticals Incorporated was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $65.00 price target on the stock.Watson Pharmaceuticals Incorporated had its price target lowered by analysts at Collins Stewart from $75.00 to $60.00. They now have a “neutral” rating on the stock.Watson Pharmaceuticals Incorporated was upgraded by analysts at Bank of America to a “buy” rating.Watson Pharmaceuticals Incorporated was upgraded by analysts at RBC Capital from a “sector perform” rating to an “outperform” rating. They now have a $66.00 price target on the stock, down previously from $67.00.Watson Pharmaceuticals Incorporated had its price target lowered by analysts at Jefferies Group to $60.00.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac...
-
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma...
-
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th...
-
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y...
-
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after...
-
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ...
-
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment